#Sovaldi

Researchers identified this association after looking at real-world data on a large group of German individuals with HIV and hep C.

Such generic drugs could save nations huge sums in the coming years.

The two-drug regimen can cure the virus in as little as eight weeks.

Hepatitis C advocate Peter McLoyd transformed his bad times into good ones.

Gilead Sciences’ HCV combo tablet regimen of Sovaldi and velpatasvir can be combined safely with most “boosted” antiretroviral treatment...

The regimen has been well-studied in combination with numerous HIV antiretrovirals (ARVs).

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.

The status was granted to the investigational pangenotypic hep C fixed-dose combination tablet of Sovaldi/velpatasivr.

Highlights from presentations at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.

Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...

Recent trials of the latest hepatitis C virus medications have brought more good news for people coinfected with HCV and HIV.

Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of...

The FDA as given priority review status to Bristol-Myers Squibb’s applications for new indication approvals for the hep C drug virus...

The real-world cure rates offered by Sovaldi (sofosbuvir)-based hep C virus regimens have not been as good as those seen in clinical trials

A look at real-world use of Bristol-Myers Squibb’s Daklinza (daclatasvir) and Gilead Sciences’ Sovaldi (sofosbuvir) showed that, among those c...

The FDA has approved AbbVie’s single-tablet combination regimen Technivie plus ribavirin to treat genotype 4 of hepatitis C virus among...